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Purpose/Objective: To evaluate feasibility in a multicentric 
setting and clinical results of a RT boost for children with 
Ependymoma and measurable residual disease after first line 
or second look surgery. 
Materials and Methods: The second AIEOP (Italian 
Association of Pediatric Hematology and Oncology) protocol 
for childhood ependymoma opened in 2003. After centralized 
pathological review, children were stratified to receive: 1) 
3D conformal RT or IMRT, 59.4 Gy/33 fractions, to the tumor 
bed in case of complete resection and grade II tumor; 2) 
same RT followed by four cycles of VEC chemotherapy in case 
of complete resection and anaplastic ependymoma; 3) VECx4, 
second look surgery whenever feasible, local RT as in 1) 
followed by a stereotactic hypofractionated (8 Gy/2 
fractions) boost to the residue still measurable after previous 
treatments. 
Results: From 2003, 143 children entered the study (median 
follow-up 60 months). In 24 children (median age 4,5 years, 
15 grade II, 20 infratentorial), out of 46 with residue after 
first surgery, second look wasn't feasible or incomplete and 
thus received VEC and 59.4 Gy to the tumor bed plus 8 Gy to 
the gross residue. 15/24 children are alive without 
progression at a median of 51 months (range 11-120 mos) 
from diagnosis, 5/6 died of local progression at a median of 
20 months, and 3 relapsed distantly, 17-23 months from 
diagnosis, and have died. No iatrogenic death or major 
toxicity occurred. 4 children, irradiated with Tomotherapy, 
developed radiation related MRI changes regressing with 
steroids within 8 months. In the 46 children with residual 
disease, 3 and 5 years PFS was 64% and 55%, and OS 80% and 
68% respectively. 3 and 5-year survival free from local 
relapse was 71% and 64% respectively. 5 year-EFS for children 
receiving the RT boost was 57%. 
Conclusions: Hypofractionated RT boost was feasible and 
contributed to obtain durable local control in 15/24 children 
with measurable residue after first line or second look 
surgery. An aggressive and integrated local treatment 
strategy, multiple surgeries and RT including an 
hypofractionated boost in case of residual disease, is 
required to improve outcome in children with Ependymoma. 
This background will be the basis of the next opening SIOP 
(Société International d'Oncologie Pediatrique) trial for 
Ependymoma.  
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Stereotactic body radiotherapy (SBRT) frequently involves the 
accurate delivery of a few large fractions to a relatively well-
defined target. The favorable anti-tumor characteristics of 
large fractions needs to be balanced against the fact that 
they are often poorly tolerated by normal organs. Although 
this means that SBRT is not possible in all clinical situations, 
in others the risks can be managed in a variety of ways 
including the use of planning and delivery techniques that 
simultaneously facilitate target coverage and organ at risk 
sparing. While the application of extremely hypo-
fractionated radiotherapy to the radical treatment of primary 
tumors is not new, current interest coincides with the 
widespread availability of advanced radiotherapy systems. 
Nonetheless, the successful paradigm of using SBRT to treat 
peripheral, early-stage lung cancer has yet to be replicated 
in other clinical scenarios. Against this background the 
present talk aims to briefly outline the essential features of 
SBRT; describe the historical aspects of extreme hypo-
fractionation for radical treatments; succinctly review the 
current literature on SBRT for treating primary tumors; 
discuss some of the challenges in using SBRT for this 
indication; and touch on future perspectives. 
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Metastases account for approximately 80–90% of cancer 
deaths. Systemic therapies (either cytotoxic chemotherapy or 
targeted agents), the cornerstone for treatment in 
metastatic disease, are rather than curative. Therefore, 
novel therapies for the treatment of patients with metastatic 
cancer are needed. 
In 1995, Hellmann and Weichselbaum coined the term 
“oligometastases” to describe a less-advanced (or 
“intermediate”) state of metastatic disease, peculiarly 
situated between locoregionally-confined and widely-
metastatic cancer. In this paradigm, a limited burden of 
metastatic disease may be amenable to potentially curative 
local therapies.  
Stereotactic Body RadioTherapy (SBRT), which is also 
referred to as Stereotactic Ablative Radiotherapy (SABR), is a 
form of high-precision radiotherapy, tipically delivered in one 
to 8 fractions, commonly using fraction sizes of 7.5 Gy or 
more. SBRT allows for target dose-escalation (thus increasing 
tumor control), while minimizing normal tissue exposure 
(thus minimizing the toxicity risk). When compared to 
surgery, SBRT has the theoretical advantage to be less 
invasive and more effective, because of  lower morbidity 
rates, lower costs and the potential for delivering ablative 
treatments on an outpatient basis. 
